Slow-onset inhibition of the fabI enoyl reductase from francisella tularensis: Residence time and in vivo activity

ACS Chemical Biology

Volumn 4, Issue 3, 2009, Pages 221-231

  Lu, Hao ^a   England, Kathleen ^b   Ende, Christopher Am ^a   Truglio, James J ^a   Luckner, Sylvia ^c   Reddy, B Gopal ^a   Marlenee, Nicole L ^b   Knudson, Susan E ^b   Knudson, Dennis L ^b   Bowen, Richard A ^b   Kisker, Caroline ^c   Slayden, Richard A ^b   Tonge, Peter J ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b Veterinary Dentistry and Oral Surgery   (United States)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; DIPHENYL ETHER; ENOYL REDUCTASE; ENZYME INHIBITOR; OXIDOREDUCTASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL SURVIVAL; BACTERIAL VIABILITY; CHEMOTHERAPY; CLONING; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME INHIBITOR COMPLEX; FATTY ACID SYNTHESIS; FRANCISELLA TULARENSIS; IN VIVO STUDY; INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; THERMODYNAMICS; TULAREMIA;

ANIMALS; ANTI-BACTERIAL AGENTS; CRYSTALLOGRAPHY, X-RAY; DISEASE MODELS, ANIMAL; DRUG DESIGN; ENOYL-(ACYL-CARRIER-PROTEIN) REDUCTASE (NADH); ENZYME INHIBITORS; FATTY ACID SYNTHESIS INHIBITORS; FATTY ACID SYNTHETASE COMPLEX, TYPE II; FEMALE; FRANCISELLA TULARENSIS; MICE; MICE, INBRED ICR; PHENYL ETHERS; STRUCTURE-ACTIVITY RELATIONSHIP; TRICLOSAN; TULAREMIA;

BACTERIA (MICROORGANISMS); FRANCISELLA TULARENSIS; MAMMALIA; NEGIBACTERIA;

EID: 65249139978     PISSN: 15548929     EISSN: None     Source Type: Journal    
DOI: 10.1021/cb800306y     Document Type: Article

References (46)

1. Sjostedt, A. (2006) Intracellular survival mechanisms of Francisella tularensis, a stealth pathogen, Microbes Infect. 8, 561-567.
2. Oyston, P. C., Sjostedt, A., and Titball, R. W. (2004) Tularaemia: bio-terrorism defence renews interest in Francisella tularensis, Nat. Rev. Microbiol. 2, 967-978.
3. White, S. W., Zheng, J., Zhang, Y. M., and Rock (2005) The structural biology of type II fatty acid biosynthesis, Annu. Rev. Biochem. 74, 791-831.
4. Bergler, H., Fuchsbichler, S., Hogenauer, G., and Turnowsky, F. (1996) The enoyl-[acyl-carrier-protein] reductase (FabI) of Escherichia coli, which catalyzes a key regulatory step in fatty acid biosynthesis, accepts NADH and NADPH as cofactors and is inhibited by palmitoyl-CoA, Eur. J. Biochem. 242, 689 - 694.
5. Zhang, Y. M., White, S. W., and Rock, C. O. (2006) Inhibiting bacterial fatty acid synthesis, J. Biol. Chem. 281,17541-17544.
6. Heath, R. J., and Rock, C. O. (2004) Fatty acid biosynthesis as a target for novel antibacterials, Curr. Opin. Invest. Drugs 5,146-153.
7. Campbell, J. W., and Cronan, J. E., Jr. (2001) Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery, Annu. Rev. Micro-biol. 55, 305-332.
8. Payne, D. J., Warren, P. V., Holmes, D. J., Ji, Y., and Lonsdale, J. T. (2001) Bacterial fatty-acid biosynthesis: a genomics-driven target for antibacterial drug discovery, Drug Discovery Today 6, 537-544.
9. Seefeld, M. A., Miller, W. H., Newlander, K. A., Burgess, W. J., DeWolf, W. E., Jr., Elkins, P. A., Head, M. S., Jakas, D. R., Janson, C. A., Keller, P. M., Manley, P. J., Moore, T. D., Payne, D. J., Pearson, S., Polizzi, B. J., Qiu, X., Rittenhouse, S. F., Uzinskas, I. N., Wallis, N. G., and Huffman, W. F. (2003) Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK, J. Med. Chem. 46, 1627-1635.
10. Karlowsky, J. A., Laing, N. M., Baudry, T., Kaplan, N., Vaughan, D., Hoban, D. J., and Zhanel, G. G. (2007) In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis, Antimicrob. Agents Chemother. 51,1580-1581.
11. Lu, H., and Tonge, P.J. (2008) Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway, Acc. Chem. Res. 41, 11-20.
12. Moir, D.T. (2005) Identification of inhibitors of bacterial enoyl-acyl carrierprotein reductase, Curr. Drug Targets Infect. Disord. 5, 297-305.
13. Heath, R.J., Li, J., Roland, G. E., and Rock, C. O. (2000) Inhibition of the Staphylococcus aureus NADPH-dependentenoyl-acyl carrier protein reductase by triclosan and hexachlorophene, J. Biol. Chem. 275, 4654-4659.
14. McMurry, L. M., McDermott, P. F., and Levy, S. B. (1999) Genetic evidence that InhA of Mycobacterium smegmatis is a target for tri-closan, Antimicrob. Agents Chemother. 43, 711-713.
15. McMurry, L. M., Oethinger, M., and Levy, S. B. (1998) Triclosan targets lipid synthesis, Nature 394, 531-532.
16. Parikh, S. L.,Xiao, G., and Tonge, P.J. (2000) Inhibition of InhA, the enoylreductasefrom Mycobacterium tuberculosis, by triclosan and isoniazid, Biochemistry39, 7645-7650.
17. Stewart, M. J., Parikh, S., Xiao, G., Tonge, P. J., and Kisker, C. (1999) Structural basis and mechanism of enoyl reductase inhibition by triclosan, J. Mol. Biol. 290, 859-865.
18. Ward, W. H., Holdgate, G. A., Rowsell, S., McLean, E. G., Pauptit, R. A., Clayton, E., Nichols, W. W., Colls, J. G., Minshull, C. A., Jude, D. A., Mistry, A., Timms, D., Camble, R., Hales, N. J., Britton, C.J., and Taylor, I. W. (1999) Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase bytriclosan, Biochemistry 38,12514-12525.
19. Copeland, R. A., Pompliano, D. L., and Meek, T. D. (2006) Drug-target residence time and its implications for lead optimization, Nat. Rev. Drug Discovery 5, 730-739.
20. Tummino, P. J., and Copeland, R. A. (2008) Residence time of receptor-ligand complexes and its effect on biological function, Biochemistry47, 8465.
21. Sivaraman, S., Zwahlen, J., Bell, A. F., Hedstrom, L., and Tonge, P. J. (2003) Structure-activity studies of the inhibition of FabI, the enoyl reductase from Escherichia coli, by triclosan: kinetic analysis of mutant FabIs, Biochemistry 42,4406-4413.
22. Levy, C. W., Roujeinikova, A., Sedelnikova, S., Baker, P. J., Stuitje, A. R., Slabas, A. R., Rice, D. W., and Rafferty, J. B. (1999) Molecular basis of triclosan activity, Nature 398,383-384.
23. Kuo, M. R., Morbidoni, H. R., Alland, D.,Sneddon,S. F., Gourlie, B. B., Staveski, M. M., Leonard, M., Gregory, J. S., Janjigian, A. D., Yee, C., Musser, J. M., Kreiswirth, B., Iwamoto, H., Perozzo, R., Jacobs, W. R., Jr., Sacchettini, J. C., and Fidock, D.A. (2003) Targeting tuberculosis and malaria through inhibition of enoyl reductase: compound activity and structural data, I. Biol. Chem. 278, 20851-20859.
24. Perozzo, R., Kuo, M., Sidhu, A. S., Valiyaveettil, J. T., Bittman, R., Jacobs, W. R., Jr., Fidock, D. A., and Sacchettini, J. C. (2002) Structural elucidation of the specificity of the antibacterial agent triclosan for malarial enoyl acyl carrier protein reductase, J. Biol. Chem. 277, 13106-13114.
25. Sivaraman, S., Sullivan, T. J., Johnson, F., Novichenok P., Cui, G., Simmerling, C., and Tonge, P.J. (2004) Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues, J. Med. Chem. 47, 509-518.
26. Sullivan, T. J., Truglio, J. J., Boyne, M. E., Novichenok, P., Zhang, X., Stratton, C. F., Li, H. J., Kaur, T., Amin, A., Johnson, F., Slayden, R. A., Kisker, C., and Tonge, P.J. (2006) High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis, ACS Chem. Biol. 1,43-53.
27. Baldock, C., Rafferty, J. B., Sedelnikova, S. E., Baker, P. J., Stuitje, A. R., Slabas, A. R., Hawkes, T. R., and Rice, D. W. (1996) A mechanism of drug action revealed by structural studies of enoyl reductase, Science 274, 2107-2110.
28. Rafi, S. B., Cui, G., Song, K., Cheng, X., Tonge, P. J., and Simmerling, C. (2006) Insight through molecular mechanics Poisson-Boltzmann surface area calculations into the binding affinity of triclosan and three analogues for FabI, the E. coli enoyl reductase, J. Med. Chem. 49,4574-4580.
29. Morrison, J. F., and Walsh, C. T. (1988) The behavior and significance of slow-binding enzyme inhibitors, Adv. Enzymol. Relat. Areas Mol. Biol. 61, 201-301.
30. Copeland, R. A. (2005) Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists (Methods of Biochemical Analysis), Wiley, Hoboken, NJ.
31. Swinney, D. C. (2004) Biochemical mechanisms of drug action: what does it take for success? Nat. Rev. Drug Discovery 3, 801-808.
32. Lewandowicz, A., Tyler, P. C., Evans, G. B., Furneaux, R. H., and Schramm, V. L. (2003) Achieving the ultimate physiological goal in transition state analogue inhibitors for purine nucleoside phosphorylase, J. Biol. Chem. 278, 31465-31468.
33. Tonge, P. J., Kisker, C., and Slayden, R. A. (2007) Development of modern InhA inhibitors to combat drug resistant strains of Mycobacterium tuberculosis, Curr. Top. Med. Chem. 7,489-498.
34. Xu, H., Sullivan, T.J., Sekiguchi,J., Kirikae, T., Ojima, I.,Stratton, C. F., Mao, W., Rock, F. L., Alley, M. R., Johnson, F., Walker, S. G., and Tonge, P.J. (2008) Mechanism and inhibition of saFabI, the enoyl reductase from Staphylococcus aureus, Biochemistry 47, 4228-4236.
35. am Ende, C. W., Knudson, S. E., Liu, N., Childs, J., Sullivan, T. J., Boyne, M., Xu, H., Gegina, Y., Knudson, D. L., Johnson, F., Peloquin, C. A., Slayden, R. A., and Tonge, P. J. (2008) Synthesis and in vitro anti-mycobacterial activity of B-ring modified diaryl ether InhA inhibitors, Bioorg. Med. Chem. Lett. 18, 3029-3033.
36. McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., and Read, R.J. (2007) Phasercrystallographic software, J. Appl. Crystallogr. 40,658-674.
37. Emsley, P., and Cowtan, K. (2004) Coot: model-building tools for molecular graphics, Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132.
38. Winn, M. D., Isupov, M. N., and Murshudov, G. N. (2001) Use of TLS parameters to model anisotropic displacements in macromolecular refinement, Acta Crystallogr. D Biol. Crystallogr. 57,122-133.
39. Bosio, C. M., and Dow, S. W. (2005) Francisella tularensis induces aberrant activation of pulmonary dendritic cells, J. Immunol. 175, 6792-6801.
40. Baker, C. N., Hollis, D. G., and Thornsberry, C. (1985) Antimicrobial susceptibility testing of Francisella tularensis with a modified Mueller-Hinton broth, J. Clin. Microbiol. 22, 212-215.
41. Franzblau, S. G., Witzig, R. S., McLaughlin, J. C., Torres, P., Madico, G., Hernandez, A., Degnan, M. T., Cook, M. B., Quenzer, V. K., Ferguson, R. M., and Gilman, R. H. (1998) Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay, J. Clin. Microbiol. 36, 362-366.
42. Boyne, M. E., Sullivan, T. J., am Ende, C. W., Lu, H., Gruppo, V., Heaslip, D., Amin, A. G., Chatterjee, D., Lenaerts, A., Tonge, P. J., and Slayden, R. A. (2007) Targeting fatty acid biosynthesis for the development of novel chemotherapeutics against Mycobacterium tuberculosis: evaluation of A-ring-modified diphenyl ethers as high- affinity InhA inhibitors, Antimicrob. Agents Chemother. 51, 3562-3567.
43. Krissinel, E., and Henrick, K. (2004) Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions, Acta Crystallogr. D Biol. Crystallogr. 60, 2256-2268.
44. Bailey, S. (1994) The Ccp4 Suite-programs for protein crystallography, Acta Crystallogr. Sect. D Biol. Crystallogr. D50 760-763.
45. Delano, W. L. ((2002)) The PyMOL Molecular Graphics System; http://www.pymol.org.
46. Hofstein, H. A., Feng, Y., Anderson, V. E., and Tonge, P. J. (1999) Role of glutamate 144 and glutamate 164 in the catalytic mechanism of enoyl-CoAhydratase, Biochemistry 38,9508-9516.